Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2472-2472 ◽  
Author(s):  
Kristie A. Blum ◽  
Jeffrey A. Jones ◽  
Leslie Andritsos ◽  
Joseph M. Flynn ◽  
Deidre Deam ◽  
...  

Abstract Abstract 2472 Background: As a result of the previously demonstrated efficacy of the cyclin dependent kinase inhibitor, flavopiridol, and the immunomodulatory agent, lenalidomide, in heavily pre-treated patients (pts) with bulky adenopathy and adverse cytogenetics, we conducted a phase I trial to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of combined therapy. Both agents are active in pts with relapsed/refractory cytogenetically high risk CLL, utilize different novel mechanisms of action, and do not deplete T-cells, leading to the potential development of a well tolerated regimen for pts with del (17p13.1) and del (11q22.3) with greater efficacy and less infectious toxicity than observed with currently accepted fludarabine or alemtuzumab combinations. Methods: Pts with histologically confirmed CLL relapsed after at least 1 prior therapy with a WBC ≤ 150,000/mm3, ANC ≥ 1000/mm3, platelets ≥ 30,000/mm3, and creatinine ≤ 1.5 mg/dL were enrolled. Treatment consisted of flavopiridol alone (30 mg/m2 bolus + 50 mg/m2 4-hour continuous IV infusion (CIVI)) days 1, 8, and 15 of cycle 1 to decrease the pre-treatment disease burden and minimize the potential risks of simultaneous tumor flare and tumor lysis syndrome (TLS) with concurrent lenalidomide and flavopiridol. Starting in cycle 2, flavopiridol 30 mg/m2 bolus + 30 mg/m2 4-hour CIVI days 3, 10, and 17 was combined with lenalidomide 2.5, 5.0, 7.5, 10, 15, or 25 mg days 1–21 every 28 days. All pts received 20 mg of dexamethasone 30 minutes prior to flavopiridol dosing and 4 mg of dexamethasone 24 hours after flavopiridol to minimize cytokine release symptoms. Results: Twenty-one pts (12 males) with a median age of 59 (range 42–71) previously treated with a median of 4 prior therapies (range 1–10) were enrolled. All pts received prior fludarabine, 9 pts were fludarabine refractory, no pts previously received flavopiridol, and 1 pt was previously treated with lenalidomide. Pts had Rai stage I/II (n=6) or IV (n=15) disease and 13 pts had bulky adenopathy ≥ 5 cm. Thirteen pts had del (17p13.1) and 8 pts had del (11q22.3). Seventeen pts completed two or more cycles of therapy (median 3, range 2–8), receiving 2.5 mg (n=6), 5.0 mg (n=7), and 7.5 mg (n=4) of lenalidomide. Four pts completed only one cycle of therapy and were removed prior to receiving lenalidomide due to progressive disease (n=2), TLS requiring dialysis (n=1), and grade 4 thrombocytopenia (n=1). DLT consisting of grade 3–4 transaminitis persisting > 7 days occurred in 2 pts treated with 2.5 mg (n=1) and 5.0 mg of lenalidomide (n=1), respectively. Grade 3–4 toxicities consisted of neutropenia (86%), diarrhea (62%), transaminitis reversible in ≤ 7 days (57%), anemia (38%), thrombocytopenia (38%), hyperglycemia (38%), infection without neutropenia (24%, cellulitis in 1 pt, pneumonia in 3 pts, and catheter-associated in 1 pt), febrile neutropenia (14%, unknown source in 2 pts and pneumonia in 1 pt), TLS not requiring dialysis (14%), and fatigue (14%). Grade 1 tumor flare occurred in 1 pt and did not require additional steroids or cessation of lenalidomide. In 15 evaluable pts who completed 1 or more cycles of combined lenalidomide and flavopiridol, partial responses were observed in 7 pts, including 4 pts with del (17p13.1), 3 pts with del (11q22.3), 5 fludarabine-refractory pts, 3 pts with bulky lymphadenopathy ≥ 5 cm, and 1 pt previously treated with lenalidomide. Conclusions: Combined flavopiridol and lenalidomide is well tolerated, with activity in pts with previously treated, cytogenetically high-risk CLL. The MTD has not been reached and dose escalation continues. This trial is supported by NCI R21 CA133875, NCI K23 CA109004, NCI U01 CA076576, LLS SCOR 7080-06, and the D. Warren Brown Foundation. Disclosures: Blum: Celgene: Research Funding. Off Label Use: The efficacy of the cyclin dependent kinase inhibitor, flavopiridol, and the immunomodulatory agent, lenalidomide, are under investigation in CLL.

2013 ◽  
Author(s):  
Sanjeev Kumar Shangary ◽  
Gandhali Deshpande ◽  
Vinay Sonawane ◽  
Venkatesha Venkatasubbaiah ◽  
Archana Jalota-Badhwar ◽  
...  

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4827-4827 ◽  
Author(s):  
Asher Alban Chanan-Khan ◽  
Blanche Mavromatis ◽  
Kanti R. Rai ◽  
Philomena Casey ◽  
Steven Novick ◽  
...  

Abstract Bcl-2 is an anti-apoptotic protein closely linked to chemotherapy resistance and inferior survival in patients (pts) with CLL. Genasense(GNS) enhances apoptosis induced by fludarabine (F), dexamethasone, and rituximab (R) in vitro, and has limited single-agent activity in heavily pre-treated CLL pts. Down-regulation of Bcl-2 may further sensitize CLL cells to apoptosis induced by F and R without exposing subjects to the toxicity of alkylating agents. CLL and NHL pts occasionally exhibit a “cytokine release syndrome” (spiking fever, back pain, and occasional hypotension) with GNS treatment. We hypothesized that a “step dosing” approach with GNS, similar to that sometimes used for R, could ameliorate these effects and allow safe and effective combination of this agent with F and R. We are currently evaluating this combination in pts with either previously untreated (UT) or relapsed, previously treated (PT) CLL who require systemic treatment. Eligibility includes: plts ≥ 50,000/mm3; serum Cr ≤ 1.5 mg/dL; adequate organ function; negative Coombs; no history of autoimmune hemolytic anemia. In cycle 1, GNS is given by continuous intravenous infusion at 1.5 mg/kg/d days 1 to 7. R is given on a dose-escalating schema (day 4, 125 mg/m2; day 6, 250 mg/m2). F (25 mg/m2/d) is given on days 6 to 8. In subsequent 28-day cycles (up to 6), the dose of GNS is escalated to 3 mg/kg/d days 1 to7 days, with R 375 mg/m2 on day 5 and F days 5 to7. To date, 20 pts have been enrolled (17 PT and 3 UT). Characteristics included: median age, 62 yrs (range 39 to 82 yrs); Rai stage III (2 pts) and IV (6 pts). Prior to administration of either F or R, single-agent GNS treatment at the initial reduced dose in Cycle 1 resulted in a median decrease in lymphocytes of 15% (among all patients regardless of decline in lymphocyte count) (Baseline: 48.3 cells x 103/ml; day 4: 40.1 cells x 103/ml). For the 13 pts who experienced a decline in lymphocyte count in cycle 1 prior to F and R, the median percentage change was 17%, with 4 pts having a > 25% decrease. Three PT pts discontinued from study treatment prior to completing 6 cycles, 2 due to disease progression, and 1 with Grade 3 thrombocytopenia that was unresolved after 4 weeks. Among the 20 pts treated to date (9 ongoing), the most common grade 3 or higher adverse events have been neutropenia, pyrexia and thrombocytopenia. Serious adverse events have been noted in only 6 of 20 pts (all PT pts) and have included 2 pts with fever (1 neutropenic), 2 R infusion reactions, 1 lymph node abscess and 1 tumor lysis syndrome (with sepsis). Conclusions: 20 pts have been treated with combination GNS, F and R. Single-agent activity with GNS has been observed at a reduced dose of 1.5 mg/kg/d in cycle 1. The “step dosing” approach appears to be a well-tolerated, alternative approach to the administration of GNS. Further details of safety and efficacy will be presented.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1378-1378
Author(s):  
Deborah M Stephens ◽  
Amy S. Ruppert ◽  
Kristie A. Blum ◽  
Jeffrey A. Jones ◽  
Joseph M. Flynn ◽  
...  

Abstract Abstract 1378 Although the most rapidly growing portion of the United States population is the elderly (Yancik R and Ries L, Semin Oncol 2004), they are consistently underrepresented in cancer clinical trials (Hutchins L et al, N Engl J Med 1999). The incidence of chronic lymphocytic leukemia (CLL) is markedly increased in older people, with a median age at diagnosis of 72 years (Ries L et al, SEER Clinical Statistics Review 2008). In contrast, an age range of between 58 and 66 years has been noted in patients (pts) enrolled in key trials to evaluate the first-line treatment for CLL (Eichhorst B et al, Leuk Lymphoma 2009). Both fludarabine and chemoimmunotherapy with rituximab have not demonstrated much promise in the older subset of patients. Developing new therapeutics that have clinical benefit and also demonstrate feasibility of administration to this patient population is of great interest. Flavopiridol, is a pan-cyclin-dependent kinase inhibitor, that has demonstrated significant clinical activity in relapsed and refractory CLL pts including those with del(17p13.1)(Christian B et al, Clin Lymphoma Myeloma 2009). We sought to determine the feasibility and impact of treating patients over the age of 70 with flavopiridol by reviewing outcomes of two clinical trials using single-agent flavopiridol in patients with relapsed or refractory CLL at our institution (Byrd J et al, Blood 2007; Lin T et al, J Clin Oncol 2009). Pts were divided into categories based on age [≥70 years old (n = 21) and <70 years old (n = 95)]. Of the 21 pts aged 70 or older, all but one (95%) presented with Rai Stage III/IV compared with 76% of the younger pts (<70 years old; P = 0.07). Older age was also associated with complex karyotype (63% vs. 37%; P = 0.04). No significant difference was observed in response rates, with 43% of older pts achieving response vs. 47% of younger pts (P = 0.81). The estimated median progression free survival (PFS) for both age groups was 0.8 years (P = 0.9). In multivariable analyses, there remained no significant differences in response rates or PFS when controlling for treatment schedule, Rai stage and presence of complex karyotype (P = 0.76 and P = 0.89, respectively). Although overall survival tended to be worse in the older pts compared with the younger pts (estimated medians of 2.1 and 2.4 years, respectively), following adjustment for other variables in a multivariable analysis, this difference was no longer significant (P = 0.54, hazard ratio = 1.20 [95% CI: 0.7 – 2.1]). With respect to toxicities, no significant difference in occurrence of tumor lysis syndrome (TLS) or cytokine release syndrome (CRS) was observed between the two age groups, TLS occurred in 48% of older pts and 45% of younger pts (P = 1.00), while CRS occurred in 33% of older pts and 36% of younger pts (P = 1.00). As for infection, only 29% of older pts experienced this toxicity compared to 62% of younger pts (P = 0.007). In multivariable pharmacokinetic (PK) analyses of a patient subset (n=56), there were no significant associations observed between PK parameters and age when controlling for age, bilirubin level, alanine transaminase level, platelet count, white blood cell count, BUN, and 14 distinct single nucleotide polymorphisms. These data demonstrate that flavopiridol administration to older CLL patients is both feasible, acceptably tolerated, and has similar efficacy as compared to younger patients. Future development of treatment approaches with both single-agent and combination strategies of flavopiridol should be considered for older CLL patients. Disclosures: Off Label Use: The efficacy of the cyclin dependent kinase inhibitor, flavopiridol is under investigation in CLL. Jones:GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbott Laboratories: Research Funding.


Leukemia ◽  
2004 ◽  
Vol 18 (4) ◽  
pp. 747-755 ◽  
Author(s):  
I N Hahntow ◽  
F Schneller ◽  
M Oelsner ◽  
K Weick ◽  
I Ringshausen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document